Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
about
Urologic cancer in Japan: role of Japan at the frontier of issues in AsiaInfluence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer PatientsCharacteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.Pharmacotherapies for renal cell carcinoma in Japan.Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice.Sunitinib DDI with paracetamol, diclofenac, mefenamic acid and ibuprofen shows sex-divergent effects on the tissue uptake and distribution pattern of sunitinib in mice.Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports.
P2860
Q26798350-F52788B9-52C8-4484-838A-7413B669F4C1Q28080163-5847AD37-732F-4612-8027-C91C20DF2A1CQ33440354-C4E0A971-E35B-4BA3-AF5D-BA0C4708D2C0Q37097532-DA772EA9-50D5-4B42-9BAC-B2729AEE954EQ38635940-17181EEB-7CDC-44FB-85AA-BD7B9828C2D2Q38668274-A5A2AB7C-F8AF-49B2-8EE5-2609D83036D1Q40836247-388000F0-A8DB-456C-8365-DAFA6390B397Q47831824-27BACF9A-4B8D-42C1-83BC-8204A5245B2CQ47895186-388F21BD-A74A-4489-A42A-5680B6411149Q48029427-77D0F5E9-6AF4-40D5-86D7-9A37132D1139Q49822908-4C7BFED2-38A6-4000-9CCB-B99460564241Q55234953-4B05D335-80F3-48EF-8B62-2E78C5E0DCA0
P2860
Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Real-world use of sunitinib in ...... in 1689 consecutive patients.
@ast
Real-world use of sunitinib in ...... in 1689 consecutive patients.
@en
type
label
Real-world use of sunitinib in ...... in 1689 consecutive patients.
@ast
Real-world use of sunitinib in ...... in 1689 consecutive patients.
@en
prefLabel
Real-world use of sunitinib in ...... in 1689 consecutive patients.
@ast
Real-world use of sunitinib in ...... in 1689 consecutive patients.
@en
P2093
P2860
P356
P1476
Real-world use of sunitinib in ...... in 1689 consecutive patients.
@en
P2093
Hideyuki Akaza
Hiroyuki Houzawa
Kouji Aoki
Naomi Ueno
Sang-Yoon Lee
Seiji Naito
Susan Pitman Lowenthal
P2860
P304
P356
10.1093/JJCO/HYV045
P577
2015-04-27T00:00:00Z